瘢痕疙瘩病灶内药物注射治疗的研究进展  

Advances in the research of drug intralesional injection therapy in keloid

作　　者：郭琪格 姚敏[1] Guo Qige;Yao Min(Department of Plastic Surgery, NO. 9 People＇s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China)

机构地区：[1]上海交通大学医学院附属第九人民医院整复外科,200011

出　　处：《中华烧伤杂志》2018年第6期415-418,共4页Chinese Journal of Burns

摘　　要：瘢痕疙瘩是以真皮层内Fb过度增殖、ECM大量沉积、表皮结构异常为特点的皮肤纤维增生性、病理性疾病，病因不清，常有皮肤损伤等诱因，具有发病率高、治愈率低等特点，并且易复发。该病症好发于胸、肩、颈、背与耳廓，临床表现主要包括瘢痕色红、凸出于正常皮肤并呈浸润性生长，严重者造成关节和肢体功能障碍，另伴皮肤瘙痒、疼痛等不适。由于瘢痕疙瘩的发病机制至今尚不明确，尚无完全有效的疗法，因此一直是外科治疗和研究的难点。Keloid is characterized by tumor-like invasive growth, high incidence, and low remission rate. The pathogenesis of keloid is still unknown. Keloids can not only affect appearance, but also cause severe itching and pain, which may affect physical and mental health of patients. Previous treatments for keloids include surgery, drugs, lasers and so on. Due to the high recurrence rate of surgical treatment accompanied by keloid enlargement, drug therapy has gradually become a hot topic. Among various methods of administration, intralesional injection is widely accepted as it can promote drug absorption to achieve better results. The progress of several drugs used in intralesional injection therapy for keloid is reviewed in this paper.

关 键 词：瘢痕疙瘩 成纤维细胞 病灶内注射 

分 类 号：R622[医药卫生—整形外科]